Literature DB >> 15944274

Augmentation of cutaneous immune responses by ATP gamma S: purinergic agonists define a novel class of immunologic adjuvants.

Richard D Granstein1, Wanhong Ding, Jing Huang, Aton Holzer, Richard L Gallo, Anna Di Nardo, John A Wagner.   

Abstract

Extracellular nucleotides activate ligand-gated P2XR ion channels and G protein-coupled P2YRs. In this study we report that intradermal administration of ATPgammaS, a hydrolysis-resistant P2 agonist, results in an enhanced contact hypersensitivity response in mice. Furthermore, ATPgammaS enhanced the induction of delayed-type hypersensitivity to a model tumor vaccine in mice and enhanced the Ag-presenting function of Langerhans cells (LCs) in vitro. Exposure of a LC-like cell line to ATPgammaS in the presence of LPS and GM-CSF augmented the induction of I-A, CD80, CD86, IL-1beta, and IL-12 p40 while inhibiting the expression of IL-10, suggesting that the immunostimulatory activities of purinergic agonists in the skin are mediated at least in part by P2Rs on APCs. In this regard, an LC-like cell line was found to express mRNA for P2X(1), P2X(7), P2Y(1), P2Y(2), P2Y(4), P2Y(9), and P2Y(11) receptors. We suggest that ATP, when released after trauma or infection, may act as an endogenous adjuvant to enhance the immune response, and that P2 agonists may augment the efficacy of vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944274     DOI: 10.4049/jimmunol.174.12.7725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response.

Authors:  Ali R Djalilian; David McGaughey; Satyakam Patel; Eun Young Seo; Chenghua Yang; Jun Cheng; Melanija Tomic; Satrajit Sinha; Akemi Ishida-Yamamoto; Julia A Segre
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

Review 2.  Dendritic cells and contact dermatitis.

Authors:  Yoshinori Sasaki; Setsuya Aiba
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 3.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

4.  Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP.

Authors:  Takehito Kobayashi; Hideaki Kouzaki; Hirohito Kita
Journal:  J Immunol       Date:  2010-05-05       Impact factor: 5.422

Review 5.  Pathomechanisms of Contact Sensitization.

Authors:  Philipp R Esser; Stefan F Martin
Journal:  Curr Allergy Asthma Rep       Date:  2017-11-11       Impact factor: 4.806

6.  Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.

Authors:  Julio A Diaz-Perez; Meaghan E Killeen; Yin Yang; Cara D Carey; Louis D Falo; Alicia R Mathers
Journal:  J Invest Dermatol       Date:  2018-06-02       Impact factor: 8.551

Review 7.  Dendritic cell metabolism.

Authors:  Edward J Pearce; Bart Everts
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

8.  Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity.

Authors:  Felix C Weber; Philipp R Esser; Tobias Müller; Jayanthi Ganesan; Patrizia Pellegatti; Markus M Simon; Robert Zeiser; Marco Idzko; Thilo Jakob; Stefan F Martin
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

9.  Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.

Authors:  Meaghan E Killeen; Laura Ferris; Erine A Kupetsky; Louis Falo; Alicia R Mathers
Journal:  J Immunol       Date:  2013-03-11       Impact factor: 5.422

10.  Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity.

Authors:  Wanhong Ding; Lori L Stohl; John A Wagner; Richard D Granstein
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.